Welcome to our dedicated page for Assertio Holdings SEC filings (Ticker: ASRT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Assertio Holdings, Inc. filings document formal disclosures for a Nasdaq-listed commercial pharmaceutical company, including material-event reports, annual meeting voting results, governance actions, and capital-structure matters. The record includes disclosures on common stock, convertible senior notes, tender-offer communications, and amendments to equity incentive plan provisions.
Assertio's SEC reports also cover material definitive agreements and completed asset-sale disclosures involving branded products such as INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP. These filings describe transaction documents, Regulation FD communications, shareholder approvals, executive-compensation plan matters, and operating subjects tied to the company's pharmaceutical commercialization business.
Assertio Holdings, Inc. and Garda Therapeutics mutually agreed to delay the launch of Garda’s tender offer to acquire all outstanding Assertio shares until May 14, 2026, aligning with an amended and restated merger agreement. The cash offer remains at $21.80 per share, valuing the deal at $153.2 million. Assertio also plans to delay its previously announced tender offer for all outstanding Convertible Senior Notes to May 14, 2026 and expects to file its Schedule 14D-9 on that date.
Assertio Holdings, Inc. reported results of its 2026 Annual Meeting of Stockholders held on May 5, 2026. Stockholders approved an amendment and restatement of the Amended and Restated 2014 Omnibus Incentive Plan to increase shares available for issuance by 400,000 shares.
All six director nominees were elected to serve until the 2027 annual meeting, each receiving over 1.74 million votes for. Stockholders also approved, on an advisory basis, the compensation of named executive officers and ratified Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stark David Matthew reported acquisition or exercise transactions in this Form 4 filing.
Assertio Holdings, Inc. director David Matthew Stark received a grant of 4,851 shares of Common Stock in the form of restricted stock units as director compensation. These RSUs vest in full on the earlier of the first anniversary of the grant date or the next annual stockholders’ meeting that occurs at least 50 weeks after the prior year’s meeting. Following this award, Stark directly holds 11,420 shares. The reported share amounts have been adjusted to reflect the company’s 1-for-15 reverse stock split completed on December 26, 2025.
Emany Sravan Kumar reported acquisition or exercise transactions in this Form 4 filing.
Assertio Holdings, Inc. director Sravan Kumar Emany received a grant of 4,851 shares of Common Stock in the form of restricted stock units at no purchase price. These units vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders that is at least 50 weeks after the prior year's meeting. Following this award, he directly holds 23,855 shares of Common Stock. All reported share amounts reflect a 1-for-15 reverse stock split that became effective on December 26, 2025.
Kirk Sigurd reported acquisition or exercise transactions in this Form 4 filing.
Assertio Holdings, Inc. director Kirk Sigurd received a grant of 4,851 shares of Common Stock in the form of restricted stock units at a price of $0.00 per share. Following this award, he directly holds 12,017 shares.
The restricted stock units vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders that is at least 50 weeks after the prior year’s annual meeting, consistent with the company’s Nonemployee Director Compensation & Grant Policy. All reported share amounts reflect a 1-for-15 reverse stock split effected on December 26, 2025.
MCKEE WILLIAM reported acquisition or exercise transactions in this Form 4 filing.
Assertio Holdings, Inc. director William McKee received an equity award of 4,851 shares of common stock in the form of restricted stock units, granted at no cash cost. These units vest in full on the earlier of the first anniversary of the grant date or the next annual stockholders meeting that is at least 50 weeks after the prior year’s meeting. Following this grant, McKee holds 27,936 shares of common stock directly. The reported share amounts reflect a 1-for-15 reverse stock split the company effected on December 26, 2025.
Mason Heather L reported acquisition or exercise transactions in this Form 4 filing.
Assertio Holdings, Inc. director Heather L. Mason received an equity award in the form of 4,851 shares of common stock on the date of the company’s 2026 Annual Meeting of Stockholders. The shares were granted at no cash cost to her as a compensation award.
These shares are restricted stock units that vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting that occurs at least 50 weeks after the prior year’s meeting. After this award, she directly holds 27,610 common shares, adjusted for a 1-for-15 reverse stock split that took effect on December 26, 2025.
Assertio Holdings, Inc. announced that it and Garda Therapeutics, Inc. mutually agreed to postpone the start of Garda’s tender offer to acquire all outstanding Assertio shares until May 8, 2026.
Under the amended and restated merger agreement, Garda plans to acquire Assertio for $21.80 per share in cash, representing total cash consideration of $153.2 million. Assertio also plans to postpone the previously announced tender offer for all outstanding Convertible Senior Notes to May 8, 2026 and expects to file its Schedule 14D‑9 relating to the tender offer on that date.
Assertio Holdings entered into an amended merger agreement to be acquired by Garda Therapeutics for $21.80 per share in cash. The board unanimously approved the transaction and recommended that stockholders tender their shares. The offer must commence on or before May 4, 2026 and requires at least a majority of shares tendered and at least $95,000,000 of Closing Net Cash. The agreement removes a contingent value right previously included at an $18.00 per-share proposal and includes customary termination fees and financing commitments.
Assertio Holdings, Inc. entered into an amended and restated merger agreement with Garda Therapeutics that raises the all‑cash tender offer price to $21.80 per share for all outstanding common stock, with no contingent value right. The Board unanimously approved the deal and recommended that stockholders tender their shares. The offer must start on or before May 4, 2026 and will initially run for 20 business days, followed by a second‑step merger at the same cash price if the tender succeeds. Closing conditions include a majority of shares being tendered, minimum Closing Net Cash of $95 million, and customary legal and regulatory conditions, supported by $22.2 million of equity commitments and up to $130 million of debt financing. The agreement also sets reciprocal $5.81 million termination fees and provides for a tender offer to repurchase $40 million of 6.50% Convertible Notes due 2027 at 100% of principal plus accrued interest.